Lake Street Advisors Group LLC Increases Position in Bristol-Myers Squibb (NYSE:BMY)

Lake Street Advisors Group LLC boosted its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 20.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,722 shares of the biopharmaceutical company’s stock after acquiring an additional 2,498 shares during the period. Lake Street Advisors Group LLC’s holdings in Bristol-Myers Squibb were worth $833,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Bradley & Co. Private Wealth Management LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $49,000. Longbow Finance SA lifted its holdings in shares of Bristol-Myers Squibb by 5.0% in the 4th quarter. Longbow Finance SA now owns 54,908 shares of the biopharmaceutical company’s stock valued at $3,106,000 after buying an additional 2,600 shares during the period. Canton Hathaway LLC boosted its position in Bristol-Myers Squibb by 43.2% in the 4th quarter. Canton Hathaway LLC now owns 995 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 300 shares in the last quarter. Todd Asset Management LLC purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth about $326,000. Finally, Exchange Capital Management Inc. lifted its position in shares of Bristol-Myers Squibb by 26.8% during the 4th quarter. Exchange Capital Management Inc. now owns 54,533 shares of the biopharmaceutical company’s stock valued at $3,084,000 after buying an additional 11,531 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Performance

NYSE BMY opened at $57.34 on Thursday. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The company has a market cap of $116.35 billion, a P/E ratio of -12.97, a P/E/G ratio of 2.07 and a beta of 0.45. The stock has a 50-day moving average of $57.06 and a two-hundred day moving average of $54.58. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $61.10.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. As a group, analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were issued a $0.62 dividend. The ex-dividend date was Friday, January 3rd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 dividend on an annualized basis and a yield of 4.33%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -56.11%.

Insiders Place Their Bets

In related news, EVP Samit Hirawat acquired 1,823 shares of the stock in a transaction dated Friday, February 14th. The stock was acquired at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the transaction, the executive vice president now owns 63,932 shares in the company, valued at $3,506,030.88. This represents a 2.94 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.09% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Citigroup increased their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Bank of America reissued a “neutral” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Daiwa America raised shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 13th. Daiwa Capital Markets upgraded shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a report on Wednesday, November 13th. Finally, Jefferies Financial Group upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and raised their price target for the stock from $63.00 to $70.00 in a report on Monday, December 16th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $57.86.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.